Quality of life (QOL) for patients treated with FOLFOX with or without cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147.
M. R. Mahoney
No relevant relationships to disclose
J. A. Sloan
No relevant relationships to disclose
J. M. Hubbard
No relevant relationships to disclose
H. Liu
No relevant relationships to disclose
A. F. Shields
No relevant relationships to disclose
E. Chan
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Genentech; ImClone Systems; Pfizer; Sanofi
Research Funding - Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech; Idera Pharmaceuticals; ImClone Systems; Lilly; Merck; MethylGene; Pfizer
R. M. Goldberg
No relevant relationships to disclose
S. Gill
No relevant relationships to disclose
M. S. Kahlenberg
No relevant relationships to disclose
S. G. Nair
No relevant relationships to disclose
D. J. Sargent
No relevant relationships to disclose
S. R. Alberts
No relevant relationships to disclose